Yiyuan Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yiyuan Guo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Jie Zheng
Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2 shared publications - Lixia Feng
Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2 shared publications Xilong Wang
Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2 shared publicationsBendong Shi
College of Veterinary Medicine, Northeast Agricultural University, Harbin, People’s Republic of China
1 shared publicationBinger Zhao
College of Veterinary Medicine, Northeast Agricultural University, Harbin, People’s Republic of China
1 shared publicationBo Li
College of Veterinary Medicine, Northeast Agricultural University, Harbin, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 5 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11743
Correction to: A novel mechanism of chlorogenic acid against type 2 diabetes‑induced diabetic retinopathy: suppressing ferroptosis via NRF2/xCT/GPX4 and STAT3 signaling
- 5 May 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11743
Open AccessCorrection to: A novel mechanism of chlorogenic acid against type 2 diabetes‑induced diabetic retinopathy: suppressing ferroptosis via NRF2/xCT/GPX4 and STAT3 signaling
- 23 February 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11721-11741
A novel mechanism of chlorogenic acid against type 2 diabetes-induced diabetic retinopathy: suppressing ferroptosis via NRF2/xCT/GPX4 and STAT3 signaling
Diabetic retinopathy (DR) is a common microvascular complication of type 2 diabetes (T2D), driven by hyperglycemia-induced oxidative stress, ferroptosis, and inflammatory signaling. Here, we demonstrate that chlorogenic acid (CGA) ameliorates T2D and DR by simultaneously modulating the NRF2/xCT/GPX4 antioxidant pathway and the p-STAT3/xCT/GPX4 inflammatory-ferroptosis axis. High-fat diet (HFD) combined with streptozotocin (STZ)-induced T2D mice and high-glucose (HG)-stimulated human retinal microvascular endothelial cells (HRMECs) were used to evaluate the effects of CGA in vivo and in vitro. Network pharmacology, molecular docking, Western blotting, immunofluorescence, Seahorse metabolic assays, and site-directed mutagenesis were employed to investigate the underlying molecular mechanisms. CGA treatment significantly improved systemic metabolic parameters, including fasting blood glucose, HbA1c, and insulin sensitivity, while reducing anxiety-like behavior in T2D mice. Histological analyses revealed that CGA alleviated retinal structural abnormalities and decreased lipid droplet accumulation. Mechanistically, CGA activated NRF2/xCT/GPX4 signaling to enhance antioxidant defenses and suppress ferroptosis, while inhibiting STAT3 phosphorylation, reducing pro-inflammatory cytokines, and modulating xCT/GPX4 expression. In HRMECs, NRF2 inhibition or STAT3 activation attenuated CGA’s protective effects, highlighting the critical roles of these pathways. Molecular docking and CETSA analyses further identified N485 of STAT3 as a key residue mediating CGA binding and functional regulation. These findings indicate that CGA exerts multi-modal protective effects against DR by targeting oxidative stress, ferroptosis, and inflammation. This study provides mechanistic insight into CGA as a potential therapeutic candidate for T2D-associated retinal complications and underscores the broader relevance of NRF2 and STAT3 pathways as intervention targets in diabetes-related microvascular disorders.
- 23 February 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11721-11741
A novel mechanism of chlorogenic acid against type 2 diabetes-induced diabetic retinopathy: suppressing ferroptosis via NRF2/xCT/GPX4 and STAT3 signaling
Diabetic retinopathy (DR) is a common microvascular complication of type 2 diabetes (T2D), driven by hyperglycemia-induced oxidative stress, ferroptosis, and inflammatory signaling. Here, we demonstrate that chlorogenic acid (CGA) ameliorates T2D and DR by simultaneously modulating the NRF2/xCT/GPX4 antioxidant pathway and the p-STAT3/xCT/GPX4 inflammatory-ferroptosis axis. High-fat diet (HFD) combined with streptozotocin (STZ)-induced T2D mice and high-glucose (HG)-stimulated human retinal microvascular endothelial cells (HRMECs) were used to evaluate the effects of CGA in vivo and in vitro. Network pharmacology, molecular docking, Western blotting, immunofluorescence, Seahorse metabolic assays, and site-directed mutagenesis were employed to investigate the underlying molecular mechanisms. CGA treatment significantly improved systemic metabolic parameters, including fasting blood glucose, HbA1c, and insulin sensitivity, while reducing anxiety-like behavior in T2D mice. Histological analyses revealed that CGA alleviated retinal structural abnormalities and decreased lipid droplet accumulation. Mechanistically, CGA activated NRF2/xCT/GPX4 signaling to enhance antioxidant defenses and suppress ferroptosis, while inhibiting STAT3 phosphorylation, reducing pro-inflammatory cytokines, and modulating xCT/GPX4 expression. In HRMECs, NRF2 inhibition or STAT3 activation attenuated CGA’s protective effects, highlighting the critical roles of these pathways. Molecular docking and CETSA analyses further identified N485 of STAT3 as a key residue mediating CGA binding and functional regulation. These findings indicate that CGA exerts multi-modal protective effects against DR by targeting oxidative stress, ferroptosis, and inflammation. This study provides mechanistic insight into CGA as a potential therapeutic candidate for T2D-associated retinal complications and underscores the broader relevance of NRF2 and STAT3 pathways as intervention targets in diabetes-related microvascular disorders.
- Open Access
- 10 December 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
SIRT3 deficiency exacerbates cognitive decline by disrupting mitochondrial antioxidant homeostasis in D-galactose-induced aging mice
Age-related cognitive decline poses a growing clinical burden, with mitochondrial oxidative stress recognized as a key mediator. Sirtuin 3 (SIRT3), a mitoc
- 10 December 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessSIRT3 deficiency exacerbates cognitive decline by disrupting mitochondrial antioxidant homeostasis in D-galactose-induced aging mice
Age-related cognitive decline poses a growing clinical burden, with mitochondrial oxidative stress recognized as a key mediator. Sirtuin 3 (SIRT3), a mitoc
- 26 November 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (46) , 15038-15046
Corneal retention using a nanorobot-based eyedrop
We present a nanorobot-based eyedrop that offers active retention on the corneal surface. This active delivery platform significantly enhances the antifungal efficacy against fungal keratitis.
- 26 November 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (46) , 15038-15046
Corneal retention using a nanorobot-based eyedrop
We present a nanorobot-based eyedrop that offers active retention on the corneal surface. This active delivery platform significantly enhances the antifungal efficacy against fungal keratitis.
- 30 October 2025
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 1-17
A novel anti-acute lung injury mechanism of astilbin: inhibition of epithelial cells ferroptosis by targeting NRF2 activation via binding Val608 site of NRF2
Objective and design Astilbin (ATB) is a newly discovered natural compound with anti-inflammatory and immunomodulatory effects. However, its effects and underlying mechanisms in acute lung injury (ALI) remain unclear. Material or subjects An ALI model was established by intratracheal injection of lipopolysaccharide (LPS) into the trachea of C57BL/6 mice. In vitro, MLE-12 cells were stimulated with LPS. ATB was administered as a pretreatment to C57BL/6 mice and MLE-12 cells. Results ATB significantly alleviated ALI and suppressed the inflammatory response induced by LPS. Further data suggested that ATB inhibited LPS-induced ferroptosis in epithelial cells by increasing GPX4 and xCT expression. Moreover, ATB promoted NRF2 nuclear translocation in the LPS-treated group, while NRF2 inhibition significantly reversed the protective effects of ATB on ferroptosis and inflammation. NRF2 knockout in vivo abolished the protective effects of ATB against ALI and epithelial cell ferroptosis. Mechanistically, ATB increased NRF2 activity by binding to the Val608 amino acid of NRF2. The effect of ATB in improving ALI and ferroptosis was significantly reduced in NRF2 Val608 mutant mice. Conclusion ATB mitigated ALI by suppressing epithelial cell ferroptosis and activating the NRF2 pathway via binding to Val608 of NRF2.
- 30 October 2025
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 1-17
A novel anti-acute lung injury mechanism of astilbin: inhibition of epithelial cells ferroptosis by targeting NRF2 activation via binding Val608 site of NRF2
Objective and design Astilbin (ATB) is a newly discovered natural compound with anti-inflammatory and immunomodulatory effects. However, its effects and underlying mechanisms in acute lung injury (ALI) remain unclear. Material or subjects An ALI model was established by intratracheal injection of lipopolysaccharide (LPS) into the trachea of C57BL/6 mice. In vitro, MLE-12 cells were stimulated with LPS. ATB was administered as a pretreatment to C57BL/6 mice and MLE-12 cells. Results ATB significantly alleviated ALI and suppressed the inflammatory response induced by LPS. Further data suggested that ATB inhibited LPS-induced ferroptosis in epithelial cells by increasing GPX4 and xCT expression. Moreover, ATB promoted NRF2 nuclear translocation in the LPS-treated group, while NRF2 inhibition significantly reversed the protective effects of ATB on ferroptosis and inflammation. NRF2 knockout in vivo abolished the protective effects of ATB against ALI and epithelial cell ferroptosis. Mechanistically, ATB increased NRF2 activity by binding to the Val608 amino acid of NRF2. The effect of ATB in improving ALI and ferroptosis was significantly reduced in NRF2 Val608 mutant mice. Conclusion ATB mitigated ALI by suppressing epithelial cell ferroptosis and activating the NRF2 pathway via binding to Val608 of NRF2.